Shire Health secures UK Flomax contract

Yamanouchi Pharma has hired Shire Health London (SHL) to handle UK communications for Flomax, its market-leading product to treat benign prostatic hyperplasia (BPH).

The agency will handle UK healthcare professional and consumer communications aimed at boosting sales of Flomax, the most widely prescribed treatment in its field.

The campaign also aims to raise awareness of the BPH condition among both healthcare professionals and patients.

Symptoms of BPH include the frequent need to urinate, particularly at night, and a hesitant, interrupted or weak urine stream.

SHL managing director Matt de Gruchy, associate director Sian Boisseau and programme manager Helen Limbrick are working on the account.

Flomax launched in Japan in 1993 and is now marketed in more than 60 countries.

SHL worked on a one-off direct-to-consumer campaign, which ran under the slogan ‘Time to Go’, for Yamanouchi last year.

The campaign was fronted by BBC football pundit Alan Hansen and backed by Peter Baker, director at charity Men’s Health Forum.

Details for this year’s PR offensive are yet to be finalised.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in